Pharma Exclusives Pressreleases
Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 Diabetes
Wednesday, December 18, 2024Biomea Fusion Inc a clinicalstage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to improve the lives of patients with diabetes obesity and genetically defined cancers today announced positive topline...
Eton Pharmaceuticals Announces Final Readout of PKU GOLIKE® Clinical Trial
Tuesday, December 17, 2024Eton Pharmaceuticals Inc an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases announced the full readout and compelling results from the clinical trial evaluating PKU GOLIKE as a protein substitu...
Gilead and Terray Therapeutics Announce Multi-Target Research Collaboration to Discover and Develop Novel Small Molecule Therapies
Tuesday, December 17, 2024Gilead Sciences Inc and Terray Therapeutics Inc announced today that the companies have entered into a strategic collaboration to discover and develop novel small molecule therapies across multiple targets
Teva Announces New Patient Access Program with Direct Relief to Provide Access to Inhalers for Uninsured Patients
Thursday, December 12, 2024Teva Pharmaceuticals Inc a US affiliate of Teva Pharmaceutical Industries Ltd announced today the launch of a new patient access program in partnership with Direct Relief to supply inhalers to eligible patients in the United States free of charge
CARVYKTI® Significantly Improved Minimal Residual Disease Negativity Compared to Standard of Care for Patients with Relapsed or Refractory Multiple Myeloma
Tuesday, December 10, 2024Legend Biotech Corporation a global leader in cell therapy announced today new results from the Phase CARTITUDE study that show a single infusion of CARVYKTI ciltacabtagene autoleucel ciltacel provided significantly higher rates of minimal residual...
Bristol Myers Squibb Highlights Progress of Cell Therapy Portfolio at ASH 2024 with Long-Term Survival Data and Results from Expanding Pipeline
Tuesday, December 10, 2024Bristol Myers Squibb announced results from presentations reinforcing its leadership in cell therapy with data demonstrating efficacy durability and safety of currently available therapies in blood cancers and highlighting the potential of its pipel...
Takeda Strengthens Oncology Pipeline with Elritercept through Licensing Agreement with Keros Therapeutics
Tuesday, December 03, 2024Takeda today announced that it has entered into an exclusive licensing agreement with Keros Therapeutics Inc to further develop manufacture and commercialize elritercept worldwide outside of mainland China Hong Kong and Macau Elritercept is a latesta...
Gilead and Tubulis Enter Into Exclusive Option and License Agreement to Develop ADC Candidate for Select Solid Tumor Target
Tuesday, December 03, 2024Gilead Sciences Inc and Tubulis today announced that they have entered into an exclusive option and license agreement to discover and develop an antibodydrug conjugate ADC against a solid tumor target Through this agreement Gilead will gain access to...
